This purified ABfinity™ recombinant rabbit monoclonal antibody recognizes EGFR.ABfinity™ EGFR antibody advantages include:
• Superior lot-to-lot consistency
• Extremely high specificity and sensitivity
• Recombinant rabbit monoclonal antibody
• Validation in Western blotSpecific for EGFR
Epidermal Growth Factor Receptor (EGFR) is a 175 kDa transmembrane glycoprotein which belongs to the tyrosine kinase superfamily (Ref 2, 4). EGFR acts as a receptor for the epidermal growth factor (EGF) family (Ref 1, 2). Binding of EGFR to its ligands causes autophosphorylation of tyrosine kinase followed by activation of signal transduction of the pathways resulting in cell proliferation and differentiation (Ref 2). Deregulation of EGFR expression has been well established in several cancers including non-small cell lung carcinomas (NSCLCs) (Ref 3). Exceptional Consistency Helps Save You Time and Money
ABfinity™ antibodies are produced by transfection of mammalian cells with heavy and light chain antibody cDNAs. This provides you with high consistency between lots, minimizing the need to revalidate your assays for each lot. High Specificity Means More Reliable Data
The proprietary recombinant technology employed in the production of ABfinity™antibodies permits an extremely high degree of reliability. Staining of non-specific proteins is virtually eliminated while very high sensitivity is achieved. Invitrogen has validated this antibody in Western blotting (Figure 1). High Sensitivity Lets You Detect Low Levels of Target Protein
ABfinity™ antibodies demonstrate much higher sensitivity than ordinary antibodies. Proteins expressed in low levels can be detected with high specificity allowing you to use less of your precious samples than with ordinary antibodies. Recombinant Rabbit IgG—Use Like Any Other IgG Antibody
As with traditional IgG antibodies, gel electrophoresis of ABfinity™ antibodies produces a 150kDa band under non-reducing conditions, and 50kDa and 25kDa bands under reducing conditions.
For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use.Related Links
• Learn more about the superior performance of ABfinity™ recombinant monoclonal antibodies
• See Invitrogen's full line of ABfinity™ recombinant monoclonal antibodies
• Bridges, A.J. (1999). The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Current medicinal chemistry 6, 825-843.
• Herbst, R.S. (2004). Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology, Biology, Physics 59, 21-26.
• Raymond, E., Faivre, S., and Armand, J.P. (2000). Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 Suppl 1, 15-23; discussion 41-12.
• Zwick, E., Hackel, P.O., Prenzel, N., and Ullrich, A. (1999). The EGF receptor as central transducer of heterologous signalling systems. Trends in pharmacological sciences 20, 408-412.